A multiparameter model of primary TKI resistance. (A) Eight pretreatment features associated with differential group-specific TKI responses are summarized here and in supplemental Table 27. For each feature, we provide a heatmap of the average degree of enrichment in each of the control and prognostic groups (supplemental Table 27), a technology platform for assessing each feature (mass or flow cytometry, or scRNA-seq), and whether the feature increases or decreases across groups. (B) Schematic summarizing the biological features contributing to heterogeneous TKI responses, including LSC/HSPC-, NK cell–, and tumor microenvironment–dependent factors.